Marks’ exit at FDA rattles an already teetering biotech industry

Drew Armstrong

Executive Editor

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

The departure of one of the FDA’s highest-profile regulators, whose career was defined by advancing new technologies to patients, rattled investors and companies who were …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Marks’ exit at FDA rattles an already teetering biotech industry

Drew Armstrong

Executive Editor

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche CEO warns that tariffs could impact dealmaking

Versant's latest biotech focuses on inflammatory diseases

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try

Executive Editor

Senior Editor

Senior Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Marks’ exit at FDA rattles an already teetering biotech industry